• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

522 Postmarket Surveillance Studies Database

  • Print
  • Share
  • E-mail
-
The FDA has the authority to require device manufacturers to perform postmarket surveillance under Section 522 of the Food, Drugs and Cosmetics (FD&C) Act, when questions are identified for devices that meet the statutory criteria. This database contains information about 522 Postmarket Surveillance Studies that have been required. This database allows you to search information about the postmarket surveillance requirements by manufacturer or device.

Learn more...

            
  To search for Manufacturer beginning with a specific letter, select that letter
 
 A 
 B 
 C 
 D 
 E 
 F 
 G 
 H 
 I 
 J 
 L 
 M 
 N 
 O 
 P 
 R 
 S 
 T 
 U 
 V 
 W 
 X 
 Z 
 
 
   

Explant Analysis


 
Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Completed
522 Number / Requirement Number PS110093 / PSS003
Date Original Plan Accepted 12/07/2012
Date Current Plan Accepted 12/07/2012
Study Name Explant Analysis
Device Name Zweymueller-sl hip prosthesis stem
Root Document Number K871453  K032348  K033634  K033943  K974728  K003758  K053536  K071723  K091003  K091973  K063251  K071856  K073499  K081007 
General Study Protocol Parameters
Study Design Other Study Design
Data Source New Data Collection
Comparison Group Concurrent Control
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Objectives This will be an analysis of explanted devices.
Study Population Patients who undergo metal-on-metal hip implant revision
Sample Size 100 patients, 12 sites
Key Study Endpoints Explant analysis to yield failure modes
Follow-up Visits and Length of Follow-up Not applicable. This is an analysis of explanted devices.
Interim or Final Data Summary
Actual Number of Patients Enrolled 113
Actual Number of Sites Enrolled 6
Final Safety Findings The majority of failures occurred between 1 to 5 years. The main causes for revision surgery listed are: (i) pain (92%), (ii) loosening (79%), (iii) elevated cobalt and chromium ion levels in the blood (10%), (iv) presence or suspected pseudotumor (4%), and (v) osteolysis (3%).

Pronounced articular damage (scratching, pitting or bashing) was observed on 16 of 113 cups (14%) and 23 of 113 heads (20%). In 6 instances, cups and heads with pronounced articular damage were paired together. Articular discoloration/sta ining was observed on 59 of 113 cups (52%) and 90 of 113 heads (80%). In terms of impingement, there were 11 stem necks available for observation. Some form of circumferential marking was present on 6 of the stem necks (55%). Some form of rim marking was noted on 27 of 113 cups (24%). In three cases, both the cup and stem showed marking. A wear scar extending through the rim of the cup was observed in 10 of the 113 cases (9%) analyzed.

Total taper wear varied from 0.1 to 24mm3, with an average taper wear of 2.5 mm3. All taper wear greater than 10mm3 occurred past 3 years. Goldberg scores >2 were observed on 8 of 113 head tapers (7.1%), 7 of 113 taper adapter outer surfaces (6.2%) and 83 of 113 taper adapter inner surfaces (73%).
Final Effectiveness Findings Not applicable, explant analysis study focused on safety.
Study Strengths and Weaknesses A prominent strength of the study is its adequate sample size. A weakness of the study is the absence of complete clinical data in all cases.
Recommendations for Labeling Changes No labeling changes are recommended because the device is no longer marketed.


Explant Analysis Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
18 month report 06/06/2014 06/06/2014 On Time
2 yr report 12/06/2014 12/11/2014 Overdue/Received
3 yr report 12/06/2015 12/09/2015 Overdue/Received
42 month report 07/05/2016 07/05/2016 On Time
4 yr report 12/05/2016 12/05/2016 On Time
54 month report 06/04/2017 06/01/2017 On Time
5 yr report 12/05/2017 12/18/2017 Overdue/Received
66 month report 06/05/2018 06/07/2018 Overdue/Received


Contact Us


Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources


-
-